82 related articles for article (PubMed ID: 16039311)
1. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT.
Raspollini MR; Pinzani P; Simi L; Amunni G; Villanucci A; Paglierani M; Taddei GL
Gynecol Oncol; 2005 Aug; 98(2):334-5. PubMed ID: 16039311
[No Abstract] [Full Text] [Related]
2. The protooncogene c-KIT is expressed in leiomyosarcomas of the uterus.
Raspollini MR; Paglierani M; Taddei GL; Villanucci A; Amunni G; Taddei A
Gynecol Oncol; 2004 Jun; 93(3):718. PubMed ID: 15196872
[No Abstract] [Full Text] [Related]
3. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
[TBL] [Abstract][Full Text] [Related]
4. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
5. Imatinib is not a potential alternative treatment for uterine leiomyosarcoma.
Serrano C; Mackintosh C; Herrero D; Martins AS; de Alava E; Hernández T; Pérez-Fontán J; Abad M; Pérez A; Serrano E; Bullón A; Orfao A
Clin Cancer Res; 2005 Jul; 11(13):4977-9; author reply 4979-80. PubMed ID: 16000598
[No Abstract] [Full Text] [Related]
6. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.
Wang L; Felix JC; Lee JL; Tan PY; Tourgeman DE; O'Meara AT; Amezcua CA
Gynecol Oncol; 2003 Aug; 90(2):402-6. PubMed ID: 12893208
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
8. C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus.
Raspollini MR; Villanucci A; Amunni G; Paglierani M; Taddei A; Taddei GL
J Chemother; 2003 Feb; 15(1):81-4. PubMed ID: 12678420
[TBL] [Abstract][Full Text] [Related]
9. C-kit protein expression in uterine and ovarian mesenchymal tumours.
Erdogan G; Bassorgun CI; Pestereli HE; Simsek T; Karaveli S
APMIS; 2007 Mar; 115(3):204-9. PubMed ID: 17367465
[TBL] [Abstract][Full Text] [Related]
10. Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma.
Kubo T; Sugita S; Wada R; Kikuchi N; Iwasaki M; Ito Y; Sugawara T; Fujita H; Emori M; Tanaka R; Hirano H; Saito T; Hasegawa T
Diagn Pathol; 2017 Mar; 12(1):26. PubMed ID: 28288693
[TBL] [Abstract][Full Text] [Related]
11. Comparative validation of c-kit exon 11 mutation analysis on cytology samples and corresponding surgical resections of gastrointestinal stromal tumours.
Pang NK; Chin SY; Nga ME; Chang AR; Ismail TM; Omar SS; Charlton A; Salto-Tellez M
Cytopathology; 2009 Oct; 20(5):297-303. PubMed ID: 19207305
[TBL] [Abstract][Full Text] [Related]
12. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
[TBL] [Abstract][Full Text] [Related]
13. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
15. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary.
Klein WM; Kurman RJ
Int J Gynecol Pathol; 2003 Apr; 22(2):181-4. PubMed ID: 12649674
[TBL] [Abstract][Full Text] [Related]
16. HMB-45 reactivity in conventional uterine leiomyosarcomas.
Simpson KW; Albores-Saavedra J
Am J Surg Pathol; 2007 Jan; 31(1):95-8. PubMed ID: 17197924
[TBL] [Abstract][Full Text] [Related]
17. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach.
Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K
Int J Oncol; 2006 Jun; 28(6):1361-7. PubMed ID: 16685437
[TBL] [Abstract][Full Text] [Related]
18. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
20. C-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis.
Tayal S; Classen E; Bemis L; Robinson WA
Anticancer Res; 2005; 25(3B):2215-20. PubMed ID: 16158966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
